In-Depth Characterization of a Pro-Antibody-Drug Conjugate by LC-MS.

Pro-antibody-drug conjugate (PDC) is a hybrid structural format of immunoconjugate, where the structural complexity of pro-antibody and intrinsic heterogeneity of ADCs impose a prominent analytical challenge to the in-depth characterization of PDCs. In the present study, we successfully prepared and characterized PanP-DM1 as a model of PDCs, which is an anti-EGFR pro-antibody following conjugation with DM1 at lysine residues. The drug-to-antibody ratio (DAR) of PanP-DM1 was determined by LC-MS after deglycosylation, and verified by UV/vis spectroscopy. Following reduction or IdeS digestion, the pro-antibody fragments linked with DM1 were investigated by middle-down mass spectrometry. Furthermore, more than 20 modified lysine conjugation sites were determined by peptide mapping after trypsin digestion. Additionally, more than ten glycoforms of PanP-DM1 were also identified and quantified. In summary, critical quality attributes (CQAs) of PDCs including DAR, drug load distribution, and conjugation sites were fully characterized, which would contribute to the development of other PDCs for cancer treatment.

[1]  Shichen Shen,et al.  Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry. , 2017, Mass spectrometry reviews.

[2]  Davy Guillarme,et al.  Hydrophobic interaction chromatography for the characterization of monoclonal antibodies and related products. , 2016, Journal of pharmaceutical and biomedical analysis.

[3]  Guodong Chen,et al.  Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends. , 2016, Drug discovery today.

[4]  O. Heudi,et al.  Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples. , 2016, Journal of pharmaceutical and biomedical analysis.

[5]  François Debaene,et al.  Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates , 2016, Expert review of proteomics.

[6]  X. Chen,et al.  Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy , 2016, mAbs.

[7]  Q. Luo,et al.  Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate. , 2016, Analytical chemistry.

[8]  Weibin Chen,et al.  A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection , 2015, mAbs.

[9]  S. Cianférani,et al.  Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine‐linked antibody drug conjugate , 2015, Protein science : a publication of the Protein Society.

[10]  Colin D. Medley,et al.  A size exclusion-reversed phase two dimensional-liquid chromatography methodology for stability and small molecule related species in antibody drug conjugates. , 2015, Journal of chromatography. A.

[11]  A. Lazar,et al.  Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates. , 2015, Molecular Pharmaceutics.

[12]  Hao Wang,et al.  Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency , 2015, mAbs.

[13]  Ya-jun Guo,et al.  Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry , 2014, mAbs.

[14]  O. Vasiljeva,et al.  Abstract 2664: An anti-Jagged-1/-2 Probody demonstrates inhibition of Jagged-dependent Notch signaling and is activated in multiple types of tumors , 2014 .

[15]  O. Vasiljeva,et al.  Abstract 2665: Transforming Notch ligands into tumor-antigen targets: A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2 , 2014 .

[16]  H. Lowman,et al.  Probody therapeutics for targeting antibodies to diseased tissue , 2014, Expert opinion on biological therapy.

[17]  R. Borzilleri,et al.  Antibody-drug conjugates: current status and future directions. , 2014, Drug discovery today.

[18]  Yan Chen,et al.  Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. , 2014, Bioconjugate chemistry.

[19]  L. Friberg,et al.  A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer , 2014, The AAPS Journal.

[20]  Alain Beck,et al.  Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion , 2013, mAbs.

[21]  Paul H. Bessette,et al.  Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index , 2013, Science Translational Medicine.

[22]  J. Laurence,et al.  Conjugation site heterogeneity causes variable electrostatic properties in Fc conjugates. , 2013, Bioconjugate chemistry.

[23]  A. Yang,et al.  Abstract 4570: Development of a proteolytically activatable EGFR Probody for cancer therapy. , 2013 .

[24]  Yan Chen,et al.  Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy. , 2013, Methods in molecular biology.

[25]  J. Ouyang,et al.  Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography. , 2013, Methods in molecular biology.

[26]  F. Theil,et al.  Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. , 2011, Bioconjugate chemistry.

[27]  Yatin R. Gokarn,et al.  Analytical methods for physicochemical characterization of antibody drug conjugates , 2011, mAbs.

[28]  M. Sliwkowski,et al.  Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer , 2011, Breast Cancer Research and Treatment.

[29]  Aditya A Wakankar,et al.  Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. , 2010, Bioconjugate chemistry.

[30]  I. Hollander,et al.  Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. , 2008, Bioconjugate chemistry.

[31]  C. Kloft,et al.  Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. , 2007, International journal of oncology.

[32]  John M Lambert,et al.  Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry , 2005, Protein science : a publication of the Protein Society.

[33]  A. Lazar,et al.  Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. , 2005, Rapid communications in mass spectrometry : RCM.

[34]  Wei Zhang,et al.  A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. , 2005, Analytical biochemistry.